Total Funding
84
84
Total FundingPost-IPO Equity raised
Growth Score
6 pts
Heat Score
28 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
565
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
- Elisabet de los Pinos: Founder and CEOPast Role: Eli Lilly, Brand Manager Oncology Business Unit
- Natalie Holles: Chief Executive Officer and PresidentPast Role: Third Harmonic Bio, Chief Executive Officer
About the Company
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of
people with a wide range of cancers that are poorly managed today.
The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal.
Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Hispanic / Latine Founded
Hispanic / Latine Led
Women Founded
Women Led
